interferon beta-1b


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to interferon beta-1b: Interferon beta-1a

interferon

 [in″ter-fēr´on]
any of a family of glycoprotein biological response modifiers used as antineoplastic agents and immunoregulators; they inhibit cellular growth, alter the state of cellular differentiation, have effects on the cell cycle, interfere with oncogene expression, alter cell surface antigen expression, have effects on antibody production, and regulate cytotoxic effector cells.
interferon-α the major interferon produced by virus-induced leukocyte cultures; its primary producer cells are null cells, and its major activities are antiviral activity and activation of NK cells.
interferon alfa-2a a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used as an antineoplastic in the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma; administered intramuscularly or subcutaneously.
interferon alfa-2b a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used in the treatment of veneral warts, hepatitis B, and chronic hepatitis C and as an antineoplastic in the treatment of hairy cell leukemia, malignant melanoma, non-Hodgkin's lymphomas, multiple myeloma, mycosis fungoides, and AIDS-related Kaposi's sarcoma; administered intramuscularly, subcutaneously, or intralesionally.
interferon alfacon-1 a synthetic interferon related to both α and β interferons, produced by recombinant DNA technology; used in the treatment of chronic hepatitis C virus infection, administered subcutaneously.
interferon alfa-n3 a highly purified mixture of natural human interferon proteins that acts as a biologic response modifier; used in the treatment of venereal warts, administered intralesionally.
interferon-β the major interferon produced by double-stranded RNA-induced fibroblast cultures; the major producer cells are fibroblasts, epithelial cells, and macrophages, and its major activity is antiviral.
interferon beta-1a a synthetic form of interferon-β produced by recombinant DNA techniques that acts as a biologic response modifier; used in the treatment of relapsing forms of multiple sclerosis; administered intramuscularly.
interferon beta-1b a synthetic modified form of interferon-β produced by recombinant DNA techniques; used as a biologic response modifier in the treatment of relapsing forms of multiple sclerosis; administered subcutaneously.
interferon-γ the major interferon produced by lymphocyte cultures that have been immunologically stimulated by mitogens or antigens; the major producer cells are T lymphocytes, and its major activity is immunoregulation.
interferon gamma-1b a synthetic form of interferon-γ produced by recombinant technology that acts as a biologic response modifier and antineoplastic. It is used to reduce the frequency and severity of serious infections associated with chronic granulomatous disease, administered subcutaneously.

interferon beta-1b

Betaferon (UK), Betaseron, Extavia

Pharmacologic class: Biological response modifier

Therapeutic class: Antiviral, immunoregulator

Pregnancy risk category C

Action

Binds and competes with specific receptors on cell surface, inducing various interferon-induced gene products. Also inhibits proliferation of T cells.

Availability

Lyophilized powder for injection (beta-1a): 22 mcg (6 million international units; Rebif), 33 mcg (6.6 million international units; Avonex), 44 mcg (12 million international units; Rebif)

Lyophilized powder for injection (beta-1b): 0.3 mg in glass, single-use, 3-ml vial

Powder for injection (beta-1b): 0.3 mg (9.6 million international units; Betaseron)

Prefilled syringes (beta-1a): 30 mcg/0.5 ml (Avonex)

Indications and dosages

To reduce frequency of exacerbations in relapsing-remitting multiple sclerosis

Adults ages 18 and older: 8.8 mcg Rebif subcutaneously three times weekly, increased over a 4-week period to 44 mcg three times weekly. Or 30 mcg Avonex I.M. once a week. Or 8 million international units (0.25 mg) Betaseron subcutaneously every other day. Or initially, 0.0625 mg (0.25 ml) (Extavia) subcutaneously every other day, increased over 6 weeks to 0.25 mg (1 ml) every other day.

Contraindications

• Hypersensitivity to drug, its components, or albumin

Precautions

Use cautiously in:
• cardiac disease, seizure disorders, mental disorders, depression, suicidal tendencies
• women of childbearing age
• pregnant or breastfeeding patients
• children ages 18 and younger.

Administration

• Reconstitute Avonex (I.M. injection) and Rebif (subcutaneous injection) using diluent provided, according to instructions provided.
• Reconstitute Betaseron (subcutaneous injection) using 1.2 ml of diluent supplied by manufacturer, to yield a concentration of 0.25 mg/ml. Swirl gently to mix; don't shake. Use reconstituted drug within 3 hours; discard unused portion.
• Reconstitute Extavia (subcutaneous injection) by attaching prefilled, single-use syringe containing 1.2 ml of diluent supplied by manufacturer to vial using vial adapter. Slowly inject 1.2 ml of diluent into vial to yield a concentration of 0.25 mg/ml. Swirl gently to mix; don't shake. Use reconstituted drug within 3 hours; discard unused portion.

Adverse reactions

CNS: dizziness, confusion, rigors, paresthesia, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise, suicidal ideation

CV: chest pain, hypertension, palpitations, arrhythmias

EENT: visual disturbances, stye, hearing disorders, nasal congestion, sinusitis, rhinitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, eructation, stomatitis, dry mouth, intestinal obstruction

GU: gynecomastia, breast pain, early or delayed menses, menstrual bleeding or spotting, shortened duration of menstrual flow, menorrhagia

Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia

Metabolic: hypocalcemia

Musculoskeletal: joint pain, back pain, myalgia, myasthenia

Respiratory: cough, dyspnea

Skin: rash, dry skin, pruritus, flushing, alopecia, dermatitis, diaphoresis

Other: gingivitis, flulike symptoms, weight loss, edema, candidiasis, lymphadenopathy, inflammation, pain

Interactions

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, glucose, lactate dehydrogenase, neutralizing antibodies, phosphorus, uric acid: increased values

Hemoglobin, neutrophils, white blood cells: decreased values

Patient monitoring

Before therapy and monthly during therapy, assess CBC with white cell differential, glucose and electrolyte levels, and liver and kidney function tests.
• Assess fluid intake and output. Keep patient well hydrated.
• Watch for GI upset. Provide small, frequent meals to minimize nausea and vomiting.

Monitor for mental status changes, depression, and suicidal ideation.
• Evaluate for bleeding and bruising.
• Institute infection-control measures. Monitor for infection symptoms.

Patient teaching

• Teach patient or caregiver how to administer drug subcutaneously or I.M., rotate injection sites, and track dosing schedule and injection sites on calendar.
• Advise patient to avoid sources of potential infection, such as crowds and people with known infections.
• Tell patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.

Tell patient to contact prescriber immediately if depression or suicidal ideation occurs.
• Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception. Tell her to consult prescriber before breastfeeding.

Instruct patient to immediately report signs or symptoms of infection (such as fever, chills, sore throat, achiness), unusual bleeding or bruising, mental status changes, dizziness, palpitations, or chest pain.
• Tell patient he'll need regular follow-up examinations and blood tests to monitor drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

interferon beta-1b

a synthetic modified form of interferon-beta produced by recombinant DNA techniques, used as a biological response modifier in the treatment of relapsing forms of multiple sclerosis. It is administered subcutaneously.

in·ter·fer·on be·ta-1b

(intĕr-fēron bātă)
Purified protein with antiviral and immunomodulatory effects.
References in periodicals archive ?
Barkhof F van Waesberghe JH, Filippi M, Yousry T Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH; European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis.
Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
The interferon preparations are slightly different in that interferon beta-1b is produced in modified E.
Interferon beta-1b 500 [micro]g, interferon beta-1b 250 [micro]g and glatiramer acetate: primary outcomes of the Betaferon[R]/Betaseron[R] Efficacy Yielding Outcomes of a New Dose study.
Miscarriages were reported in four women who received interferon beta-1b in a clinical trial, but a causal relationship with the drug was not established.
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
A clinical trial involving 372 patients who had relapsing-remitting multiple sclerosis indicates that administering interferon beta-1b by injection every other day decreased the frequency of flare-ups and kept more patients free of flare-ups over a two-year treatment period.
The secondary endpoints of the study will assess annualized relapse rates, proportion of relapse-free patients, incidence and severity of Flu-like symptoms and incidence of antibody formation against interferon beta-1b.
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study.
Disease-modifying drugs for MS were taken by 91% of the men with RRMS (69% interferon beta-1a [intramuscularly (IM)], 6% interferon beta-1b, 12% glatiramer acetate, and 4% interferon beta-1a [subcutaneously (SQ)]) and by 49% of those with progressive forms of MS (41% interferon beta1a [IM], 8% interferon beta-1b).
Betaseron, approved in 1993, is interferon beta-1b.

Full browser ?